741814471	741814471	CD	B-NP	O
|	|	NN	I-NP	O
DH	DH	NN	I-NP	O
|	|	NN	I-NP	O
24243765	24243765	CD	I-NP	O
|	|	NN	I-NP	O
|	|	NN	I-NP	O
5330943	5330943	CD	B-NP	O
|	|	CC	I-NP	O
5/14/2007	5/14/2007	CD	I-NP	O
12	12	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
AM	AM	VBP	B-VP	O
|	|	JJ	B-NP	B-protein
atypical	atypical	JJ	I-NP	I-protein
chest	chest	NN	I-NP	I-protein
pain	pain	NN	I-NP	I-protein
,	,	,	O	O
depression/anxiety	depression/anxiety	NN	B-NP	O
|	|	NNP	I-NP	O
|	|	NNP	I-NP	O
DIS	DIS	NNP	I-NP	O
|	|	NNP	I-NP	O
Admission	Admission	NNP	I-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
10/18/2007	10/18/2007	CD	B-NP	O
Report	Report	NNP	I-NP	O
Status	Status	NNP	I-NP	O
:	:	:	O	O
Discharge	Discharge	NNP	B-NP	O
Date	Date	NNP	I-NP	O
:	:	:	O	O
1/18/2007	1/18/2007	CD	B-NP	O
******	******	SYM	I-NP	O
FINAL	FINAL	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	O	O
ZELLEFROW	ZELLEFROW	NNP	B-NP	O
,	,	,	O	O
SEAN	SEAN	NNP	B-NP	O
789-27-33-6	789-27-33-6	NNP	I-NP	O
Ber	Ber	NNP	I-NP	O
Ln	Ln	NNP	I-NP	O
.	.	.	O	O

,	,	,	O	O
Airv	Airv	NNP	B-NP	O
Heim	Heim	NNP	I-NP	O
Scotmaco	Scotmaco	NNP	I-NP	O
,	,	,	O	O
Delaware	Delaware	NNP	B-NP	O
37762	37762	CD	I-NP	O
Service	Service	NNP	I-NP	O
:	:	:	O	O
MED	MED	NNP	B-NP	O
DISCHARGE	DISCHARGE	NNP	I-NP	O
PATIENT	PATIENT	NNP	I-NP	O
ON	ON	NNP	I-NP	O
:	:	:	O	O
10/25/07	10/25/07	CD	B-NP	O
AT	AT	NN	I-NP	O
05	05	CD	I-NP	O
:	:	:	O	O
00	00	CD	B-NP	O
PM	PM	NN	I-NP	O
CONTINGENT	CONTINGENT	NN	I-NP	O
UPON	UPON	NN	I-NP	O
HO	HO	NN	I-NP	O
evaluation	evaluation	NN	I-NP	O
WILL	WILL	MD	B-VP	O
D/C	D/C	NNP	B-NP	O
ORDER	ORDER	NNP	I-NP	O
BE	BE	NNP	I-NP	O
USED	USED	NNP	I-NP	O
AS	AS	NNP	I-NP	O
THE	THE	NNP	I-NP	O
D/C	D/C	NNP	I-NP	O
SUMMARY	SUMMARY	NNP	I-NP	O
:	:	:	O	O
YES	YES	NNP	B-NP	O
Attending	Attending	NNP	I-NP	O
:	:	:	O	O
RATHJEN	RATHJEN	NN	B-NP	O
,	,	,	O	O
CLAY	CLAY	NNP	B-NP	O
MARVIN	MARVIN	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
PH.D.	PH.D.	NNP	B-NP	O
.	.	.	O	O

CODE	CODE	NN	B-NP	O
STATUS	STATUS	NNS	I-NP	O
:	:	:	O	O
Full	Full	JJ	B-NP	O
code	code	NN	I-NP	O
DISPOSITION	DISPOSITION	NN	I-NP	O
:	:	:	O	O
Home	Home	NN	B-NP	O
w	w	NN	I-NP	O
/	/	SYM	B-NP	O
services	service	NNS	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
MEDICATIONS	MEDICATIONS	NNS	I-NP	O
:	:	:	O	O
ACETYLSALICYLIC	ACETYLSALICYLIC	NN	B-NP	O
ACID	ACID	NN	I-NP	O
325	325	CD	B-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
3/7/07	3/7/07	CD	B-NP	O
by	by	IN	B-PP	O
OLDROYD	OLDROYD	NNP	B-NP	O
,	,	,	O	O
TREY	TREY	NNP	B-NP	O
W.	W.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
PH.D.	PH.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
ACETYLSALICYLIC	ACETYLSALICYLIC	NN	B-NP	O
ACID	ACID	NN	I-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
535613909	535613909	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Pt	Pt	NN	I-NP	O
.	.	.	O	O

has	have	VBZ	O	O
a	a	DT	B-NP	O
POSSIBLE	POSSIBLE	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-PP	O
IBUPROFEN	IBUPROFEN	NN	B-NP	O
;	;	:	O	O
reaction	reaction	NN	B-NP	O
is	be	VBZ	B-VP	O
Hives	Hive	NNS	B-NP	O
.	.	.	O	O

Reason	Reason	NN	B-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
pt	pt	NN	B-NP	O
tolerates	tolerate	VBZ	B-VP	O
ALBUTEROL	ALBUTEROL	NNP	B-NP	O
MDI	MDI	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ALBUTEROL	ALBUTEROL	NNP	I-NP	O
INHALER	INHALER	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
2	2	CD	I-NP	O
PUFF	PUFF	NN	I-NP	O
INH	INH	NN	I-NP	O
Q4H	Q4H	NN	I-NP	O
PRN	PRN	NN	I-NP	O
Shortness	Shortness	NN	I-NP	O
of	of	IN	B-PP	O
Breath	Breath	NNP	B-NP	O
,	,	,	O	O
Wheezing	Wheezing	NNP	B-NP	O
ALBUTEROL	ALBUTEROL	NNP	I-NP	O
NEBULIZER	NEBULIZER	NNP	I-NP	O
2.5	2.5	CD	I-NP	O
MG	MG	NNP	I-NP	O
NEB	NEB	NNP	I-NP	O
Q4H	Q4H	NNP	I-NP	O
PRN	PRN	NNP	I-NP	O
Wheezing	Wheezing	NNP	I-NP	O
NORVASC	NORVASC	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
AMLODIPINE	AMLODIPINE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
5	5	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Avoid	Avoid	NNP	I-NP	O
grapefruit	grapefruit	NN	I-NP	O
unless	unless	IN	B-SBAR	O
MD	MD	NN	B-NP	B-DNA
instructs	instruct	NNS	I-NP	I-DNA
otherwise	otherwise	RB	B-ADVP	O
.	.	.	O	O

LIPITOR	LIPITOR	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
ATORVASTATIN	ATORVASTATIN	NN	I-NP	O
-RRB-	-RRB-	,	O	O
40	40	CD	B-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BEDTIME	BEDTIME	NNP	I-NP	O
DULCOLAX	DULCOLAX	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
BISACODYL	BISACODYL	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
5	5	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
PRN	PRN	NNP	I-NP	O
Constipation	Constipation	NNP	I-NP	O
CANDESARTAN	CANDESARTAN	NNP	I-NP	O
32	32	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
DAILY	DAILY	NNP	I-NP	O
Override	Override	NNP	I-NP	O
Notice	Notice	NNP	I-NP	O
:	:	:	O	O
Override	Override	NNP	B-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
2/28/07	2/28/07	CD	B-NP	O
by	by	IN	B-PP	O
MARTA	MARTA	NN	B-NP	B-protein
,	,	,	O	O
LESTER	LESTER	NN	B-NP	O
,	,	,	O	O
M.D.	M.D.	NN	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
KCL	KCL	NNP	B-NP	O
IMMEDIATE	IMMEDIATE	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
PO	PO	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
978672386	978672386	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
CANDESARTAN	CANDESARTAN	NNP	B-NP	O
CILEXETIL	CILEXETIL	NNP	I-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
aware	aware	JJ	B-NP	O
Previous	Previous	JJ	I-NP	O
override	override	NN	I-NP	O
information	information	NN	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
2/28/07	2/28/07	CD	B-NP	O
by	by	IN	B-PP	O
FRISINA	FRISINA	NNP	B-NP	O
,	,	,	O	O
WILBURN	WILBURN	NNP	B-NP	O
D.	D.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
PH.D.	PH.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
KCL	KCL	NNP	B-NP	O
IMMEDIATE	IMMEDIATE	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
PO	PO	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
356126297	356126297	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
CANDESARTAN	CANDESARTAN	NNP	B-NP	O
CILEXETIL	CILEXETIL	NNP	I-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
will	will	MD	B-VP	O
monitor	monitor	VB	I-VP	O
Previous	Previous	JJ	B-NP	O
override	override	NN	I-NP	O
information	information	NN	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
2/28/07	2/28/07	CD	B-NP	O
by	by	IN	B-PP	O
BROWY	BROWY	NNP	B-NP	O
,	,	,	O	O
SEAN	SEAN	NNP	B-NP	O
HARLEY	HARLEY	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
KCL	KCL	NNP	B-NP	O
IMMEDIATE	IMMEDIATE	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
PO	PO	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
144469137	144469137	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
CANDESARTAN	CANDESARTAN	NNP	B-NP	O
CILEXETIL	CILEXETIL	NNP	I-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
Previous	Previous	JJ	B-NP	O
override	override	NN	I-NP	O
information	information	NN	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
2/28/07	2/28/07	CD	B-NP	O
by	by	IN	B-PP	O
COFFLAND	COFFLAND	NNP	B-NP	O
,	,	,	O	O
TERRY	TERRY	NNP	B-NP	O
ARIEL	ARIEL	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
KCL	KCL	NN	B-NP	O
IV	IV	CD	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
093068121	093068121	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
CANDESARTAN	CANDESARTAN	NNP	B-NP	O
CILEXETIL	CILEXETIL	NNP	I-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
Previous	Previous	JJ	B-NP	O
override	override	NN	I-NP	O
information	information	NN	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
9/27/07	9/27/07	CD	B-NP	O
by	by	IN	B-PP	O
GAJICA	GAJICA	NNP	B-NP	O
,	,	,	O	O
MARIA	MARIA	NNP	B-NP	O
I.	I.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
PH.D.	PH.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
KCL	KCL	NNP	B-NP	O
IMMEDIATE	IMMEDIATE	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
PO	PO	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
786561734	786561734	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
CANDESARTAN	CANDESARTAN	NNP	B-NP	O
CILEXETIL	CILEXETIL	NNP	I-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
will	will	MD	B-VP	O
monitor	monitor	VB	I-VP	O
PLAVIX	PLAVIX	NN	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	I-protein
CLOPIDOGREL	CLOPIDOGREL	NN	I-NP	I-protein
-RRB-	-RRB-	HYPH	O	I-protein
75	75	CD	B-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
DAILY	DAILY	NNP	I-NP	I-protein
COLACE	COLACE	NNP	I-NP	I-protein
-LRB-	-LRB-	NNP	I-NP	I-protein
DOCUSATE	DOCUSATE	NNP	I-NP	I-protein
SODIUM	SODIUM	NNP	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
100	100	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
BID	BID	NNP	I-NP	I-protein
ESOMEPRAZOLE	ESOMEPRAZOLE	NNP	I-NP	I-protein
20	20	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
DAILY	DAILY	NNP	I-NP	I-protein
FOLATE	FOLATE	NNP	I-NP	I-protein
-LRB-	-LRB-	NNP	I-NP	I-protein
FOLIC	FOLIC	NNP	I-NP	O
ACID	ACID	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
1	1	CD	I-NP	O
MG	MG	NN	I-NP	O
PO	PO	NN	I-NP	O
DAILY	DAILY	NN	I-NP	O
LASIX	LASIX	NN	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
FUROSEMIDE	FUROSEMIDE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
40	40	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
QAM	QAM	NNP	I-NP	O
Starting	Starting	NNP	I-NP	O
ON	ON	NNP	I-NP	O
Monday	Monday	NNP	B-NP	O
5/18/07	5/18/07	CD	B-NP	O
Instructions	Instruction	NNS	I-NP	O
:	:	:	O	O
Please	Please	NN	B-NP	B-protein
start	start	VBP	B-VP	O
this	this	DT	B-NP	O
medication	medication	NN	I-NP	O
on	on	IN	B-PP	O
Monday	Monday	NNP	B-NP	O
5/18/07	5/18/07	CD	I-NP	O
.	.	.	O	O

Alert	Alert	NNP	B-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
10/25/07	10/25/07	CD	B-NP	O
by	by	IN	B-PP	O
:	:	:	O	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
LASIX	LASIX	NN	B-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
947658081	947658081	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Pt	Pt	NN	I-NP	O
.	.	.	O	O

has	have	VBZ	O	O
a	a	DT	B-NP	O
POSSIBLE	POSSIBLE	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-PP	O
SULFA	SULFA	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
SULFONAMIDES	SULFONAMIDES	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
;	;	:	O	O
reaction	reaction	NN	B-NP	O
is	be	VBZ	B-VP	O
Unknown	Unknown	JJ	B-ADJP	O
.	.	.	O	O

Reason	Reason	NN	B-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
home	home	NN	B-NP	O
med	me	VBD	B-VP	O
GLIPIZIDE	GLIPIZIDE	NN	B-NP	B-protein
5	5	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
BID	BID	NNP	I-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
10/25/07	10/25/07	CD	B-NP	O
by	by	IN	B-PP	O
:	:	:	O	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
GLIPIZIDE	GLIPIZIDE	NN	B-NP	B-protein
PO	PO	NN	I-NP	I-protein
-LRB-	-LRB-	NN	I-NP	I-protein
ref	ref	NN	I-NP	I-protein
#	#	#	B-NP	O
270459595	270459595	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Pt	Pt	NN	I-NP	O
.	.	.	O	O

has	have	VBZ	O	O
a	a	DT	B-NP	O
POSSIBLE	POSSIBLE	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-PP	O
SULFA	SULFA	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
SULFONAMIDES	SULFONAMIDES	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
;	;	:	O	O
reaction	reaction	NN	B-NP	O
is	be	VBZ	B-VP	O
Unknown	Unknown	JJ	B-ADJP	O
.	.	.	O	O

Reason	Reason	NN	B-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
home	home	NN	B-NP	O
med	me	VBD	B-VP	O
KLOR-CON	KLOR-CON	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
KCL	KCL	NNP	I-NP	O
SLOW	SLOW	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
20	20	CD	I-NP	O
MEQ	MEQ	NN	I-NP	O
PO	PO	NN	I-NP	O
DAILY	DAILY	NN	I-NP	O
As	As	IN	B-PP	O
per	per	IN	B-PP	O
NH	NH	NNP	B-NP	O
Potassium	Potassium	NNP	I-NP	O
Chloride	Chloride	NNP	I-NP	O
Policy	Policy	NNP	I-NP	O
:	:	:	O	O
each	each	DT	B-NP	O
20	20	CD	I-NP	O
mEq	mEq	NN	I-NP	O
dose	dose	NN	I-NP	O
to	to	TO	B-VP	O
be	be	VB	I-VP	O
given	give	VBN	I-VP	O
with	with	IN	B-PP	O
4	4	CD	B-NP	O
oz	oz	NN	I-NP	O
of	of	IN	B-PP	O
fluid	fluid	JJ	B-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
10/25/07	10/25/07	CD	B-NP	O
by	by	IN	B-PP	O
:	:	:	O	O
POTENTIALLY	POTENTIALLY	NNP	B-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
CANDESARTAN	CANDESARTAN	NNP	B-NP	O
CILEXETIL	CILEXETIL	NNP	I-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
LISINOPRIL	LISINOPRIL	NNP	B-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
LISINOPRIL	LISINOPRIL	NNP	B-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
home	home	NN	B-NP	O
med	me	VBD	B-VP	O
LABETALOL	LABETALOL	NN	B-NP	B-protein
HCL	HCL	NN	I-NP	I-protein
200	200	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
BID	BID	NNP	I-NP	O
Food/Drug	Food/Drug	NNP	I-NP	O
Interaction	Interaction	NNP	I-NP	O
Instruction	Instruction	NNP	I-NP	O
Take	Take	NNP	I-NP	O
consistently	consistently	RB	B-ADVP	O
with	with	IN	B-PP	O
meals	meal	NNS	B-NP	O
or	or	CC	B-PP	O
on	on	IN	B-PP	O
empty	empty	JJ	B-NP	O
stomach	stomach	NN	I-NP	O
.	.	.	O	O

LISINOPRIL	LISINOPRIL	NN	B-NP	B-protein
80	80	CD	I-NP	I-protein
MG	MG	NNP	I-NP	I-protein
PO	PO	NNP	I-NP	I-protein
DAILY	DAILY	NNP	I-NP	O
Override	Override	NNP	I-NP	O
Notice	Notice	NNP	I-NP	O
:	:	:	O	O
Override	Override	NNP	B-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
2/28/07	2/28/07	CD	B-NP	O
by	by	IN	B-PP	O
CAPAN	CAPAN	NN	B-NP	B-protein
,	,	,	O	O
BILLIE	BILLIE	NN	B-NP	O
,	,	,	O	O
M.D.	M.D.	NN	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
KCL	KCL	NNP	B-NP	O
IMMEDIATE	IMMEDIATE	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
PO	PO	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
978672386	978672386	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
LISINOPRIL	LISINOPRIL	NNP	B-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
LISINOPRIL	LISINOPRIL	NNP	B-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
aware	aware	JJ	B-NP	O
Previous	Previous	JJ	I-NP	O
override	override	NN	I-NP	O
information	information	NN	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
2/28/07	2/28/07	CD	B-NP	O
by	by	IN	B-PP	O
BURRUEL	BURRUEL	NNP	B-NP	O
,	,	,	O	O
JOEL	JOEL	NNP	B-NP	O
C.	C.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
PH.D.	PH.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
KCL	KCL	NNP	B-NP	O
IMMEDIATE	IMMEDIATE	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
PO	PO	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
356126297	356126297	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
LISINOPRIL	LISINOPRIL	NNP	B-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
LISINOPRIL	LISINOPRIL	NNP	B-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
will	will	MD	B-VP	O
monitor	monitor	VB	I-VP	O
Previous	Previous	JJ	B-NP	O
override	override	NN	I-NP	O
information	information	NN	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
2/28/07	2/28/07	CD	B-NP	O
by	by	IN	B-PP	O
ALCONCEL	ALCONCEL	NNP	B-NP	O
,	,	,	O	O
ANDREW	ANDREW	NNP	B-NP	O
CARLTON	CARLTON	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
KCL	KCL	NNP	B-NP	O
IMMEDIATE	IMMEDIATE	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
PO	PO	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
144469137	144469137	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
LISINOPRIL	LISINOPRIL	NNP	B-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
LISINOPRIL	LISINOPRIL	NNP	B-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
Previous	Previous	JJ	B-NP	O
override	override	NN	I-NP	O
information	information	NN	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
2/28/07	2/28/07	CD	B-NP	O
by	by	IN	B-PP	O
SOCKS	SOCKS	NNP	B-NP	O
,	,	,	O	O
JAIME	JAIME	NNP	B-NP	O
CLIFTON	CLIFTON	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
KCL	KCL	NN	B-NP	O
IV	IV	CD	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
093068121	093068121	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
LISINOPRIL	LISINOPRIL	NNP	B-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
LISINOPRIL	LISINOPRIL	NNP	B-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
will	will	MD	B-VP	O
follow	follow	VB	I-VP	O
Previous	Previous	JJ	B-NP	O
override	override	NN	I-NP	O
information	information	NN	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
9/27/07	9/27/07	CD	B-NP	O
by	by	IN	B-PP	O
HAZARD	HAZARD	NNP	B-NP	O
,	,	,	O	O
NOLAN	NOLAN	NNP	B-NP	O
V.	V.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
PH.D.	PH.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
KCL	KCL	NNP	B-NP	O
IMMEDIATE	IMMEDIATE	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
PO	PO	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
786561734	786561734	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
LISINOPRIL	LISINOPRIL	NNP	B-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
POTENTIALLY	POTENTIALLY	NNP	I-NP	O
SERIOUS	SERIOUS	NNP	I-NP	O
INTERACTION	INTERACTION	NNP	I-NP	O
:	:	:	O	O
LISINOPRIL	LISINOPRIL	NNP	B-NP	O
&	&	CC	I-NP	O
POTASSIUM	POTASSIUM	NNP	I-NP	O
CHLORIDE	CHLORIDE	NNP	I-NP	O
Reason	Reason	NNP	I-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
will	will	MD	B-VP	O
monitor	monitor	VB	I-VP	O
ATIVAN	ATIVAN	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
LORAZEPAM	LORAZEPAM	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
0.5	0.5	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
PRN	PRN	NNP	I-NP	O
Anxiety	Anxiety	NNP	I-NP	O
NIFEREX	NIFEREX	NNP	I-NP	O
TABLET	TABLET	NNP	I-NP	O
150	150	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
BID	BID	NNP	I-NP	O
Number	Number	NNP	I-NP	O
of	of	IN	B-PP	O
Doses	Doses	NNP	B-NP	O
Required	Required	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
approximate	approximate	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
4	4	CD	B-NP	O
OXYCONTIN	OXYCONTIN	NN	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
OXYCODONE	OXYCODONE	NNP	I-NP	O
CONTROLLED	CONTROLLED	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
60	60	CD	I-NP	O
MG	MG	NNP	I-NP	O
PO	PO	NNP	I-NP	O
Q8H	Q8H	NNP	I-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
3/7/07	3/7/07	CD	B-NP	O
by	by	IN	B-PP	O
:	:	:	O	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
OXYCONTIN	OXYCONTIN	NN	B-NP	O
PO	PO	NN	I-NP	O
60	60	CD	I-NP	O
MG	MG	NN	I-NP	O
Q8H	Q8H	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
302667240	302667240	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Pt	Pt	NN	I-NP	O
.	.	.	O	O

has	have	VBZ	O	O
a	a	DT	B-NP	O
PROBABLE	PROBABLE	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-VP	O
MORPHINE	MORPHINE	VB	I-VP	O
CONTROLLED	CONTROLLED	VBN	B-NP	O
RELEASE	RELEASE	NN	I-NP	O
;	;	:	O	O
reaction	reaction	NN	B-NP	O
is	be	VBZ	B-VP	O
nausea	nausea	NN	B-NP	O
.	.	.	O	O

Reason	Reason	NN	B-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
pt	pt	NN	B-NP	O
tolerates	tolerate	VBZ	B-VP	O
Previous	Previous	NNP	B-NP	O
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
Override	Override	NNP	I-NP	O
added	add	VBD	B-VP	O
on	on	IN	B-PP	O
3/7/07	3/7/07	CD	B-NP	O
by	by	IN	B-PP	O
REMFERT	REMFERT	NNP	B-NP	O
,	,	,	O	O
TIM	TIM	NNP	B-NP	O
G.	G.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
PH.D.	PH.D.	NNP	B-NP	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
OXYCONTIN	OXYCONTIN	NN	B-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
966073946	966073946	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Pt	Pt	NN	I-NP	O
.	.	.	O	O

has	have	VBZ	O	O
a	a	DT	B-NP	O
PROBABLE	PROBABLE	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-VP	O
MORPHINE	MORPHINE	VB	I-VP	O
CONTROLLED	CONTROLLED	VBN	B-NP	O
RELEASE	RELEASE	NN	I-NP	O
;	;	:	O	O
reaction	reaction	NN	B-NP	O
is	be	VBZ	B-VP	O
nausea	nausea	NN	B-NP	O
.	.	.	O	O

Reason	Reason	NN	B-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
pt	pt	NN	B-NP	O
tolerates	tolerate	VBZ	B-VP	O
PERCOCET	PERCOCET	NN	B-NP	B-protein
1-2	1-2	CD	I-NP	I-protein
TAB	TAB	NN	I-NP	I-protein
PO	PO	NN	I-NP	I-protein
Q6H	Q6H	NN	I-NP	I-protein
Starting	Starting	NNP	I-NP	I-protein
Today	Today	NNP	I-NP	I-protein
-LRB-	-LRB-	NNP	I-NP	I-protein
1/9	1/9	CD	I-NP	I-protein
-RRB-	-RRB-	NNP	I-NP	I-protein
PRN	PRN	NNP	I-NP	I-protein
Pain	Pain	NNP	I-NP	I-protein
Alert	Alert	NNP	I-NP	O
overridden	overridden	JJ	I-NP	O
:	:	:	O	O
Override	Override	NN	B-NP	O
added	add	VBN	B-VP	O
on	on	IN	B-PP	O
10/25/07	10/25/07	CD	B-NP	O
by	by	IN	B-PP	O
:	:	:	O	O
on	on	IN	B-PP	O
order	order	NN	B-NP	O
for	for	IN	B-PP	O
PERCOCET	PERCOCET	NN	B-NP	O
PO	PO	NN	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
ref	ref	NN	I-NP	O
#	#	#	B-NP	O
319248763	319248763	CD	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
Pt	Pt	NN	I-NP	O
.	.	.	O	O

has	have	VBZ	O	O
a	a	DT	B-NP	O
PROBABLE	PROBABLE	NN	I-NP	O
allergy	allergy	NN	I-NP	O
to	to	TO	B-VP	O
MORPHINE	MORPHINE	VB	I-VP	O
CONTROLLED	CONTROLLED	VBN	B-NP	O
RELEASE	RELEASE	NN	I-NP	O
;	;	:	O	O
reaction	reaction	NN	B-NP	O
is	be	VBZ	B-VP	O
nausea	nausea	NN	B-NP	O
.	.	.	O	O

Reason	Reason	NN	B-NP	O
for	for	IN	B-PP	O
override	override	NN	B-NP	O
:	:	:	O	O
home	home	NN	B-NP	O
med	me	VBD	B-VP	O
SENNA	SENNA	NN	B-NP	O
TABLETS	TABLETS	NN	I-NP	O
-LRB-	-LRB-	HYPH	B-NP	O
SENNOSIDES	SENNOSIDES	NN	I-NP	O
-RRB-	-RRB-	HYPH	B-NP	O
2	2	CD	I-NP	O
TAB	TAB	NN	I-NP	O
PO	PO	NN	I-NP	O
BID	BID	NN	I-NP	O
DIET	DIET	NN	I-NP	O
:	:	:	O	O
House	House	NN	B-NP	O
/	/	SYM	B-NP	O
2	2	CD	I-NP	O
gm	gm	NN	I-NP	O
Na	Na	NN	I-NP	O
/	/	SYM	B-NP	O
Carbohydrate	Carbohydrate	NN	I-NP	O
Controlled	Control	VBN	B-VP	O
/	/	SYM	B-NP	B-protein
Low	Low	NN	I-NP	I-protein
saturated	saturate	VBD	B-VP	O
fat	fat	JJ	B-NP	O
low	low	JJ	I-NP	O
cholesterol	cholesterol	NN	I-NP	O
ACTIVITY	ACTIVITY	NN	I-NP	O
:	:	:	O	O
Walking	Walk	VBG	B-VP	O
as	as	IN	B-SBAR	O
tolerated	tolerate	VBN	B-NP	O
FOLLOW	FOLLOW	NNP	I-NP	O
UP	UP	NNP	I-NP	O
APPOINTMENT	APPOINTMENT	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
S	S	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
Please	Please	NNP	B-NP	O
call	call	VBP	B-VP	O
Psychiatry	Psychiatry	NNP	B-NP	O
outpatient	outpatient	NN	I-NP	O
clinic	clinic	NN	I-NP	O
on	on	IN	B-PP	O
Monday	Monday	NNP	B-NP	O
.	.	.	O	O

,	,	,	O	O
Please	Please	NNP	B-NP	O
call	call	VB	B-VP	O
your	your	PRP$	B-NP	O
PCP	PCP	NN	I-NP	B-protein
on	on	IN	B-PP	O
Monday	Monday	NNP	B-NP	O
to	to	TO	B-VP	O
make	make	VB	I-VP	O
an	an	DT	B-NP	O
appt	appt	NN	I-NP	O
this	this	DT	B-NP	O
week	week	NN	I-NP	O
.	.	.	O	O

,	,	,	O	O
ALLERGY	ALLERGY	NNP	B-NP	O
:	:	:	O	O
Erythromycins	Erythromycins	NNP	B-NP	O
,	,	,	O	O
Penicillins	Penicillins	NNP	B-NP	O
,	,	,	O	O
CLINDAMYCIN	CLINDAMYCIN	NNP	B-NP	O
,	,	,	O	O
IBUPROFEN	IBUPROFEN	NNP	B-NP	O
,	,	,	O	O
MORPHINE	MORPHINE	NNP	B-NP	O
CONTROLLED	CONTROLLED	NNP	I-NP	O
RELEASE	RELEASE	NNP	I-NP	O
,	,	,	O	O
SULFA	SULFA	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
SULFONAMIDES	SULFONAMIDES	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
ADMIT	ADMIT	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
:	:	:	O	O
chest	ch	JJS	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
dyspnea	dyspnea	NN	B-NP	O
on	on	IN	B-PP	O
exertion	exertion	NN	B-NP	O
PRINCIPAL	PRINCIPAL	NN	I-NP	O
DISCHARGE	DISCHARGE	NN	I-NP	O
DIAGNOSIS	DIAGNOSIS	NN	I-NP	O
;	;	:	O	O
Responsible	Responsible	JJ	B-ADJP	O
After	After	IN	B-PP	O
Study	Study	NNP	B-NP	O
for	for	IN	B-PP	O
Causing	Causing	NNP	B-NP	O
Admission	Admission	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
atypical	atypical	JJ	I-NP	O
chest	chest	NN	I-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
depression/anxiety	depression/anxiety	NN	B-NP	O
OTHER	OTHER	NNP	I-NP	O
DIAGNOSIS	DIAGNOSIS	NNP	I-NP	O
;	;	:	O	O
Conditions	Condition	NNS	B-NP	O
,	,	,	O	O
Infections	Infection	NNS	B-NP	O
,	,	,	O	O
Complications	Complication	NNS	B-NP	O
,	,	,	O	O
affecting	affect	VBG	B-VP	O
Treatment/Stay	Treatment/Stay	NNP	B-NP	O
h/o	h/o	NNP	I-NP	O
IMI	IMI	NNP	I-NP	O
Non-cardiac	Non-cardiac	JJ	I-NP	O
chest	chest	NN	I-NP	O
pain	pain	NN	I-NP	O
Lumbosacral	Lumbosacral	JJ	I-NP	O
disc	disc	NN	I-NP	O
dz	dz	NN	I-NP	O
Chronic	Chronic	JJ	I-NP	O
pain	pain	NN	I-NP	O
syndrome	syndrome	NN	I-NP	O
Migraines	Migraine	VBZ	B-VP	O
HTN	HTN	NN	B-NP	O
Anxiety	Anxiety	NN	I-NP	O
Depression	Depression	NN	I-NP	O
ALLERG	ALLERG	NN	I-NP	O
:	:	:	O	O
PCN	PCN	NN	B-NP	B-protein
,	,	,	O	O
Erythro	Erythro	NNP	B-NP	O
,	,	,	O	O
Tetracy	Tetracy	NNP	B-NP	O
S/P	S/P	NNP	I-NP	O
PTCA	PTCA	NNP	I-NP	O
1/11	1/11	CD	I-NP	O
FOR	FOR	NNP	I-NP	O
OCC	OCC	NNP	I-NP	O
RCA	RCA	NNP	I-NP	O
POSITIVE	POSITIVE	NNP	I-NP	O
ETT/MIBI	ETT/MIBI	NNP	I-NP	O
93	93	CD	I-NP	O
:	:	:	O	O
ANT/LAT	ANT/LAT	NNP	B-NP	O
WALL	WALL	NNP	I-NP	O
ISCHEMIA	ISCHEMIA	NNP	I-NP	O
OPERATIONS	OPERATIONS	NNPS	I-NP	O
AND	AND	CC	I-NP	O
PROCEDURES	PROCEDURES	NNPS	I-NP	O
:	:	:	O	O
OTHER	OTHER	NN	B-NP	O
TREATMENTS/PROCEDURES	TREATMENTS/PROCEDURES	VBZ	B-VP	O
-LRB-	-LRB-	NNP	B-NP	O
NOT	NOT	NNP	I-NP	O
IN	IN	NNP	I-NP	O
O.R.	O.R.	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
Chest	Chest	NNP	I-NP	O
x-ray	x-ray	NNP	I-NP	O
-LRB-	-LRB-	NNP	I-NP	O
3/14/07	3/14/07	CD	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
PA	PA	NN	B-NP	O
and	and	CC	O	O
lateral	lateral	JJ	B-NP	O
views	view	NNS	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
chest	chest	NN	I-NP	O
are	be	VBP	B-VP	O
compared	compare	VBN	I-VP	O
to	to	TO	B-PP	O
prior	prior	JJ	B-NP	B-DNA
dated	date	VBN	I-NP	I-DNA
10/9/06	10/9/06	CD	I-NP	I-DNA
.	.	.	O	O

Cardiomediastinal	Cardiomediastinal	JJ	B-NP	O
contours	contour	NNS	I-NP	O
are	be	VBP	B-VP	O
stable	stable	JJ	B-ADJP	O
with	with	IN	B-PP	O
mild	mild	JJ	B-NP	O
cardiomegaly	cardiomegaly	NN	I-NP	O
and	and	CC	O	O
tortuous	tortuous	JJ	B-NP	O
and	and	CC	I-NP	O
calcified	calcify	VBN	I-NP	O
aorta	aorta	NN	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
are	be	VBP	B-VP	O
no	no	DT	B-NP	O
signs	sign	NNS	I-NP	O
of	of	IN	B-PP	O
overt	overt	JJ	B-NP	O
edema	edema	NN	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
is	be	VBZ	B-VP	O
no	no	DT	B-NP	O
parenchymal	parenchymal	JJ	I-NP	O
focal	focal	JJ	I-NP	O
consolidation	consolidation	NN	I-NP	O
.	.	.	O	O

There	There	EX	B-NP	O
are	be	VBP	B-VP	O
no	no	DT	B-NP	O
pleural	pleural	JJ	I-NP	O
effusions	effusion	NNS	I-NP	O
or	or	CC	I-NP	O
pneumothoraces	pneumothorace	NNS	I-NP	O
.	.	.	O	O

Stable	Stable	JJ	B-NP	O
mild	mild	JJ	I-NP	O
cardiomegaly	cardiomegaly	NN	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
signs	sign	NNS	I-NP	O
of	of	IN	B-PP	O
failure	failure	NN	B-NP	O
.	.	.	O	O

--	--	:	O	O
--	--	:	O	O
-	-	HYPH	B-NP	O
Myocardial	Myocardial	JJ	I-NP	O
Perfusion	Perfusion	NN	I-NP	O
PET	PET	NN	I-NP	O
-LRB-	-LRB-	HYPH	O	O
3/19/07	3/19/07	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Clinical	Clinical	JJ	B-NP	O
Response	Response	NN	I-NP	O
:	:	:	O	O
Non-ischemic	Non-ischemic	JJ	B-ADJP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

ECG	ECG	NN	B-NP	O
Response	Response	NN	I-NP	O
:	:	:	O	O
No	No	DT	B-NP	O
ECG	ECG	NN	I-NP	O
changes	change	NNS	I-NP	O
during	during	IN	B-PP	O
infusion	infusion	NN	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Myocardial	Myocardial	JJ	B-NP	O
Perfusion	Perfusion	NN	I-NP	O
:	:	:	O	O
Abnormal	Abnormal	JJ	B-ADJP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

Global	Global	JJ	B-NP	O
LV	LV	NN	I-NP	O
Function	Function	NN	I-NP	O
:	:	:	O	O
Normal	Normal	JJ	B-ADJP	O
.	.	.	O	O

The	The	DT	B-NP	O
patient	patient	NN	I-NP	O
's	's	POS	B-NP	O
PET-CT	PET-CT	NN	I-NP	O
test	test	NN	I-NP	O
results	result	NNS	I-NP	O
are	be	VBP	B-VP	O
abnormal	abnormal	JJ	B-ADJP	O
and	and	CC	I-ADJP	O
consistent	consistent	JJ	I-ADJP	O
with	with	IN	B-PP	O
the	the	DT	B-NP	O
following	following	NN	I-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

A	A	DT	B-NP	O
small	small	JJ	I-NP	O
sized	sized	JJ	I-NP	O
region	region	NN	I-NP	O
of	of	IN	B-PP	O
myocardial	myocardial	JJ	B-NP	B-protein
scar	scar	NN	I-NP	I-protein
along	along	IN	B-PP	O
with	with	IN	B-PP	O
mild	mild	JJ	B-NP	O
residual	residual	JJ	I-NP	O
periinfarct	periinfarct	NN	I-NP	O
reversibility	reversibility	NN	I-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
distribution	distribution	NN	I-NP	O
of	of	IN	B-PP	O
the	the	DT	B-NP	O
PDA	PDA	NN	I-NP	O
coronary	coronary	JJ	I-NP	O
artery	artery	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Normal	Normal	JJ	B-NP	O
global	global	JJ	I-NP	O
LV	LV	NN	I-NP	O
systolic	systolic	JJ	I-NP	O
function	function	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

The	The	DT	B-NP	O
results	result	NNS	I-NP	O
are	be	VBP	B-VP	O
essentially	essentially	RB	B-ADJP	O
unchanged	unchanged	JJ	I-ADJP	O
from	from	IN	B-PP	O
her	her	PRP$	B-NP	O
prior	prior	JJ	I-NP	O
study	study	NN	I-NP	O
report	report	NN	I-NP	O
of	of	IN	B-PP	O
August	August	NNP	B-NP	O
,	,	,	O	O
2005	2005	CD	B-NP	O
.	.	.	O	O

--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
-	-	HYPH	B-NP	O
Renal	Renal	JJ	I-NP	B-protein
U/S	U/S	NN	I-NP	I-protein
-LRB-	-LRB-	HYPH	O	O
4/14/07	4/14/07	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
normal	normal	JJ	B-NP	O
BRIEF	BRIEF	NN	I-NP	O
RESUME	RESUME	NN	I-NP	O
OF	OF	IN	B-PP	O
HOSPITAL	HOSPITAL	JJ	B-NP	O
COURSE	COURSE	NN	I-NP	O
:	:	:	O	O
CC	CC	NN	B-NP	O
:	:	:	O	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
dyspnea	dyspnea	NN	B-NP	O
on	on	IN	B-PP	O
exertion	exertion	NN	B-NP	O
****	****	SYM	I-NP	O
HPI	HPI	NN	I-NP	O
:	:	:	O	O
Ms.	Ms.	NNP	B-NP	O
Stford	Stford	NNP	I-NP	O
is	be	VBZ	B-VP	O
a	a	DT	B-NP	O
61	61	CD	I-NP	O
yo	yo	NN	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
a	a	DT	B-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
pain	pain	NN	I-NP	O
syndrome	syndrome	NN	I-NP	O
and	and	CC	O	O
CAD	CAD	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
cath	cath	NN	I-NP	O
in	in	IN	B-PP	O
9/19	9/19	CD	B-NP	O
with	with	IN	B-PP	O
stent	stent	NN	B-NP	O
to	to	TO	B-PP	O
OM1	OM1	NN	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
,	,	,	O	O
who	who	WP	B-NP	O
presents	present	VBZ	B-VP	O
with	with	IN	B-PP	O
2	2	CD	B-NP	O
days	day	NNS	I-NP	O
of	of	IN	B-PP	O
worsening	worsen	VBG	B-VP	O
subsernal	subsernal	JJ	B-NP	O
chest	chest	NN	I-NP	O
pain	pain	NN	I-NP	O
at	at	IN	B-PP	O
rest	rest	NN	B-NP	O
.	.	.	O	O

Chest	Ch	JJS	B-NP	O
pain/pressure	pain/pressure	NN	I-NP	O
began	begin	VBD	B-VP	O
one	one	CD	B-NP	O
week	week	NN	I-NP	O
ago	ago	RB	B-ADVP	O
but	but	CC	O	O
has	have	VBZ	B-VP	O
worsened	worsen	VBN	I-VP	O
over	over	IN	B-PP	O
past	past	JJ	B-NP	O
2	2	CD	I-NP	O
days	day	NNS	I-NP	O
,	,	,	O	O
and	and	CC	O	O
has	have	VBZ	B-VP	O
had	have	VBN	I-VP	O
accompanying	accompany	VBG	I-VP	O
worsening	worsen	VBG	I-VP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
symptoms	symptom	NNS	I-NP	O
of	of	IN	B-PP	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
DOE	DOE	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
orthopnea	orthopnea	NN	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
addition	addition	NN	B-NP	O
,	,	,	O	O
she	she	PRP	B-NP	O
has	have	VBZ	B-VP	O
had	have	VBD	I-VP	O
back	back	JJ	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
pain	pain	NN	B-NP	O
in	in	IN	B-PP	O
her	her	PRP$	B-NP	O
breasts	breast	NNS	I-NP	O
,	,	,	O	O
nausea	nausea	NN	B-NP	O
,	,	,	O	O
palpitations	palpitation	NNS	B-NP	O
,	,	,	O	O
headache	headache	NN	B-NP	O
,	,	,	O	O
dizziness	dizziness	NN	B-NP	O
,	,	,	O	O
PND	PND	NN	B-NP	B-protein
,	,	,	O	O
and	and	CC	O	O
decreased	decrease	VBN	B-NP	O
appetite	appetite	NN	I-NP	O
.	.	.	O	O

Pain	Pain	NNP	B-NP	O
is	be	VBZ	B-VP	O
worse	worse	JJR	B-ADJP	O
with	with	IN	B-PP	O
inspiration	inspiration	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
denies	deny	VBZ	B-VP	O
fevers	fever	NNS	B-NP	O
,	,	,	O	O
chills	chill	NNS	B-NP	O
,	,	,	O	O
vomiting	vomit	VBG	B-VP	O
,	,	,	O	O
abdominal	abdominal	JJ	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
dysuria	dysuria	NN	B-NP	O
.	.	.	O	O

In	In	IN	B-PP	O
ED	ED	NN	B-NP	O
,	,	,	O	O
BP	BP	NN	B-NP	O
was	be	VBD	B-VP	O
initially	initially	RB	B-ADVP	O
199/119	199/119	CD	B-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
came	come	VBD	B-VP	O
down	down	RB	B-ADVP	O
to	to	TO	B-PP	O
167/90s	167/90s	CD	B-NP	O
with	with	IN	B-PP	O
one	one	CD	B-NP	O
sublingual	sublingual	JJ	I-NP	O
-LRB-	-LRB-	NN	I-NP	O
which	which	WDT	B-NP	O
did	do	VBD	B-VP	O
not	not	RB	I-VP	O
relieve	relieve	VB	I-VP	O
her	her	PRP$	B-NP	O
pain	pain	NN	I-NP	B-protein
-RRB-	-RRB-	NN	I-NP	I-protein
.	.	.	O	O

Pain	Pain	NN	B-NP	B-protein
was	be	VBD	B-VP	O
relieved	relieve	VBN	I-VP	O
by	by	IN	B-PP	O
Dilaudid	Dilaudid	NNP	B-NP	O
.	.	.	O	O

Admitted	Admit	VBN	B-VP	O
to	to	TO	B-PP	O
GMS	GMS	NN	B-NP	B-protein
for	for	IN	B-PP	O
ROMI	ROMI	NN	B-NP	B-protein
and	and	CC	I-NP	O
evaluation	evaluation	NN	I-NP	O
of	of	IN	B-PP	O
dyspnea	dyspnea	NN	B-NP	O
.	.	.	O	O

****	****	SYM	B-NP	O
PMH	PMH	NN	I-NP	O
:	:	:	O	O
Chronic	Chronic	JJ	B-NP	O
pain	pain	NN	I-NP	O
syndrome	syndrome	NN	I-NP	O
,	,	,	O	O
CAD	CAD	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
s/p	s/p	NN	I-NP	O
IMI	IMI	NN	I-NP	O
1993	1993	CD	I-NP	O
,	,	,	O	O
s/p	s/p	NN	B-NP	O
OM1	OM1	NN	I-NP	O
and	and	CC	O	O
RCA	RCA	NNP	B-NP	O
Cypher	Cypher	NNP	I-NP	O
stenting	stente	VBG	B-VP	O
in	in	IN	B-PP	O
9/19	9/19	CD	B-NP	O
-RRB-	-RRB-	NN	I-NP	O
,	,	,	O	O
DM	DM	NN	B-NP	O
,	,	,	O	O
HTN	HTN	NN	B-NP	B-protein
,	,	,	O	O
hypercholesterolemia	hypercholesterolemia	NN	B-NP	O
,	,	,	O	O
Asthma	Asthma	NN	B-NP	O
,	,	,	O	O
OSA	OSA	NN	B-NP	B-protein
,	,	,	O	O
fibromyalgia	fibromyalgia	NN	B-NP	O
,	,	,	O	O
Anxiety	Anxiety	NN	B-NP	O
,	,	,	O	O
depression	depression	NN	B-NP	O
,	,	,	O	O
hiatal	hiatal	JJ	B-NP	O
hernia	hernia	NN	I-NP	O
,	,	,	O	O
migraine	migraine	NN	B-NP	O
headaches	headache	NNS	I-NP	O
,	,	,	O	O
CHF	CHF	NN	B-NP	B-protein
with	with	IN	B-PP	O
diastolic	diastolic	JJ	B-NP	O
dysfunction	dysfunction	NN	I-NP	O
,	,	,	O	O
PMR	PMR	NN	B-NP	B-protein
,	,	,	O	O
OA	OA	NN	B-NP	O
of	of	IN	B-PP	O
knees	knee	NNS	B-NP	O
,	,	,	O	O
right	right	JJ	B-NP	O
L4-S1	L4-S1	NN	I-NP	O
radiculopathy	radiculopathy	NN	I-NP	O
****	****	SYM	B-NP	O
MEDS	MEDS	NN	I-NP	O
:	:	:	O	O
albuterol	albuterol	NN	B-NP	O
nebs/inh	nebs/inh	NN	I-NP	O
prn	prn	NN	I-NP	O
,	,	,	O	O
ASA	ASA	NN	B-NP	O
325mg	325mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
candesartan	candesartan	NN	B-NP	O
32mg	32mg	NN	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
folate	folate	JJ	B-NP	O
1mg	1mg	NN	I-NP	O
daily	daily	JJ	B-ADJP	O
,	,	,	O	O
glipizide	glipizide	NN	B-NP	O
5mg	5mg	NN	I-NP	O
BID	BID	NNP	I-NP	O
,	,	,	O	O
Klorcon	Klorcon	NNP	B-NP	O
20mEq	20mEq	NNP	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
labetalol	labetalol	NN	B-NP	O
200mg	200mg	CD	I-NP	O
BID	BID	NNP	I-NP	O
,	,	,	O	O
Lasix	Lasix	NNP	B-NP	O
40mg	40mg	NNP	I-NP	O
BID	BID	NNP	I-NP	O
,	,	,	O	O
Lipitor	Lipitor	NNP	B-NP	O
40mg	40mg	NNP	I-NP	O
QHS	QHS	NNP	I-NP	O
,	,	,	O	O
Lisinopril	Lisinopril	NNP	B-NP	O
80mg	80mg	CD	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Niferex	Niferex	NNP	B-NP	O
150mg	150mg	NNP	I-NP	O
BID	BID	NNP	I-NP	O
,	,	,	O	O
Norvasc	Norvasc	NNP	B-NP	O
5mg	5mg	IN	B-PP	O
BID	BID	NNP	B-NP	O
,	,	,	O	O
SL	SL	NNP	B-NP	O
Ntg	Ntg	NNP	I-NP	O
prn	prn	NN	I-NP	O
,	,	,	O	O
Oxycontin	Oxycontin	NN	B-NP	O
60mg	60mg	NN	I-NP	O
q8h	q8h	NN	I-NP	O
,	,	,	O	O
Percocet	Percocet	NNP	B-NP	O
5/325mg	5/325mg	CD	I-NP	O
q4-6h	q4-6h	NN	I-NP	O
prn	prn	NN	I-NP	O
,	,	,	O	O
Plavix	Plavix	NNP	B-NP	O
75mg	75mg	CD	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Protonix	Protonix	NNP	B-NP	O
20mg	20mg	CD	I-NP	O
daily	daily	RB	B-ADVP	O
,	,	,	O	O
Colace	Colace	NNP	B-NP	O
300-400mg	300-400mg	NNP	I-NP	O
TID	TID	NNP	I-NP	O
.	.	.	O	O

****	****	SYM	B-NP	O
ALL	ALL	NN	I-NP	O
:	:	:	O	O
Erythromycin	Erythromycin	NN	B-NP	O
,	,	,	O	O
PCN	PCN	NN	B-NP	B-protein
,	,	,	O	O
Clindamycin	Clindamycin	NN	B-NP	O
,	,	,	O	O
NSAIDS	NSAIDS	NN	B-NP	O
,	,	,	O	O
sulfas	sulfas	NN	B-NP	O
,	,	,	O	O
morphine	morphine	NN	B-NP	O
controlled	control	VBD	B-VP	O
release	release	NN	B-NP	O
****	****	SYM	B-NP	O
Soc	Soc	NNP	I-NP	O
hx	hx	NN	I-NP	O
:	:	:	O	O
ex-smoker	ex-smoker	NN	B-NP	O
-LRB-	-LRB-	HYPH	O	O
0.5	0.5	CD	B-NP	O
ppd	ppd	NN	I-NP	O
x	x	SYM	B-NP	O
45yrs	45yr	NNS	I-NP	O
,	,	,	O	O
quit	quit	NN	B-NP	B-protein
5yrs	5yr	NNS	I-NP	I-protein
ago	ago	RB	B-ADVP	I-protein
-RRB-	-RRB-	NN	B-NP	I-protein
,	,	,	O	O
no	no	DT	B-NP	O
EtOH	EtOH	NN	I-NP	B-protein
or	or	CC	I-NP	O
drugs	drug	NNS	I-NP	O
*****	*****	SYM	O	O
Fam	Fam	NNP	B-NP	O
Hx	Hx	NNP	I-NP	O
:	:	:	O	O
M	M	NN	B-NP	O
died	die	VBD	B-VP	O
at	at	IN	B-PP	O
62yo	62yo	CD	B-NP	O
of	of	IN	B-PP	O
kidney	kidney	NN	B-NP	O
failure	failure	NN	I-NP	O
and	and	CC	O	O
heart	heart	NN	B-NP	O
disease	disease	NN	I-NP	O
,	,	,	O	O
father	father	NN	B-NP	O
died	die	VBD	B-VP	O
at	at	IN	B-PP	O
71yo	71yo	CD	B-NP	O
of	of	IN	B-PP	O
stroke	stroke	NN	B-NP	O
and	and	CC	I-NP	O
DM	DM	NN	I-NP	O
and	and	CC	I-NP	O
heart	heart	NN	I-NP	O
disease	disease	NN	I-NP	O
****	****	SYM	B-NP	O
PE	PE	NN	I-NP	O
:	:	:	O	O
AF	AF	NN	B-NP	O
,	,	,	O	O
P-58	P-58	NN	B-NP	B-protein
,	,	,	O	O
BP	BP	NN	B-NP	B-protein
-	-	HYPH	O	O
148/90	148/90	CD	B-NP	O
,	,	,	O	O
100	100	CD	B-NP	O
%	%	NN	I-NP	O
on	on	IN	B-PP	O
1L	1L	NN	B-NP	O
,	,	,	O	O
RR-12	RR-12	NN	B-NP	B-protein
;	;	:	O	O
appears	appear	VBZ	B-VP	O
moderately	moderately	RB	B-ADJP	O
uncomfortable	uncomfortable	JJ	I-ADJP	O
.	.	.	O	O

JVP	JVP	NN	B-NP	O
flat	flat	JJ	B-ADJP	O
.	.	.	O	O

Lungs	Lung	NNS	B-NP	O
clear	clear	JJ	B-ADJP	O
;	;	:	O	O
Heart	Heart	NNP	B-NP	O
RRR	RRR	NNP	I-NP	O
,	,	,	O	O
no	no	DT	B-NP	O
murmurs	murmur	NNS	I-NP	O
.	.	.	O	O

Abd	Abd	NN	B-NP	O
soft	soft	JJ	I-NP	O
,	,	,	I-NP	O
nontender	nontender	JJ	I-NP	O
,	,	,	I-NP	O
nondistended	nondistended	JJ	I-NP	O
,	,	,	I-NP	O
+	+	JJ	I-NP	O
BS	BS	NNP	I-NP	O
.	.	.	O	O

2	2	CD	B-NP	O
+	+	SYM	I-NP	O
LE	LE	NN	I-NP	O
edema	edema	SYM	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
chronic	chronic	JJ	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
.	.	.	O	O

Strength	Strength	NN	B-NP	O
2/5	2/5	CD	I-NP	O
in	in	IN	B-PP	O
left	left	JJ	B-NP	O
leg	leg	NN	I-NP	O
due	due	JJ	B-ADJP	O
to	to	TO	B-VP	O
pain	pain	VB	I-VP	O
.	.	.	O	O

****	****	SYM	B-NP	B-protein
LABS	LABS	NN	I-NP	I-protein
:	:	:	O	O
cardiac	cardiac	JJ	B-NP	B-protein
biomarkers	biomarker	NNS	I-NP	I-protein
negative	negative	JJ	B-NP	I-protein
x3	x3	NN	I-NP	I-protein
.	.	.	O	O

Creatinine	Creatinine	NN	B-NP	O
of	of	IN	B-PP	O
1.2	1.2	CD	B-NP	O
increased	increase	VBD	B-VP	O
to	to	TO	B-PP	O
1.8	1.8	CD	B-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
trending	trend	VBG	B-VP	O
down	down	RB	B-ADVP	O
to	to	TO	B-PP	O
1.3	1.3	CD	B-NP	O
on	on	IN	B-PP	O
day	day	NN	B-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

LFTs	LFT	NNS	B-NP	O
normal	normal	JJ	B-ADJP	O
;	;	:	O	O
D-dimer	D-dimer	NN	B-NP	O
474	474	CD	I-NP	O
.	.	.	O	O

****	****	SYM	B-NP	O
EKG	EKG	NN	I-NP	O
:	:	:	O	O
NSR	NSR	NN	B-NP	B-protein
,	,	,	O	O
slightly	slightly	RB	B-NP	O
prolonged	prolonged	JJ	I-NP	O
QT	QT	NN	I-NP	O
,	,	,	O	O
Nonspecific	Nonspecific	JJ	B-NP	O
ST-Twave	ST-Twave	NN	I-NP	O
changes	change	NNS	I-NP	O
.	.	.	O	O

****	****	SYM	B-NP	O
STUDIES	STUDIES	NNS	I-NP	O
:	:	:	O	O
see	see	VB	B-VP	O
above	above	IN	B-PP	O
section	section	NN	B-NP	O
****	****	SYM	B-NP	O
IMP	IMP	NN	I-NP	O
:	:	:	O	O
60	60	CD	B-NP	O
yo	yo	NN	I-NP	O
woman	woman	NN	I-NP	O
with	with	IN	B-PP	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
CAD	CAD	NN	B-NP	B-protein
and	and	CC	O	O
chronic	chronic	JJ	B-NP	O
pain	pain	NN	I-NP	O
syndrome	syndrome	NN	I-NP	O
,	,	,	O	O
presenting	present	VBG	B-VP	O
with	with	IN	B-PP	O
2	2	CD	B-NP	O
day	day	NN	I-NP	O
history	history	NN	I-NP	O
of	of	IN	B-PP	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
and	and	CC	O	O
worsening	worsen	VBG	B-VP	O
dyspnea	dyspnea	NN	B-NP	O
on	on	IN	B-PP	O
exertion	exertion	NN	B-NP	O
.	.	.	O	O

HOSPITAL	HOSPITAL	NNP	B-NP	O
COURSE	COURSE	NNP	I-NP	O
:	:	:	O	O
1	1	CD	B-NP	O
.	.	.	O	O

CV	CV	NN	B-NP	B-protein
-LRB-	-LRB-	NN	I-NP	I-protein
I	I	PRP	B-NP	O
-RRB-	-RRB-	VBP	B-VP	O
:	:	:	O	O
With	With	IN	B-PP	O
history	history	NN	B-NP	O
of	of	IN	B-PP	O
CAD	CAD	NN	B-NP	B-protein
and	and	CC	I-NP	O
symptoms	symptom	NNS	I-NP	O
consistent	consistent	JJ	B-ADJP	O
with	with	IN	B-PP	O
new	new	JJ	B-NP	O
ischemia	ischemia	NN	I-NP	O
,	,	,	O	O
pt	pt	NN	B-NP	O
was	be	VBD	B-VP	O
admitted	admit	VBN	I-VP	O
for	for	IN	B-PP	O
ROMI	ROMI	NN	B-NP	B-protein
.	.	.	O	O

Ruled	Rule	VBN	B-VP	O
out	out	RP	B-PRT	O
with	with	IN	B-PP	O
3	3	CD	B-NP	O
sets	set	NNS	I-NP	O
of	of	IN	B-PP	O
negative	negative	JJ	B-NP	B-protein
cardiac	cardiac	JJ	I-NP	I-protein
biomarkers	biomarker	NNS	I-NP	I-protein
.	.	.	O	O

Underwent	Underwent	JJ	B-NP	O
myocardial	myocardial	JJ	I-NP	O
perfusion	perfusion	NN	I-NP	O
PET-CT	PET-CT	NN	I-NP	O
which	which	WDT	B-NP	O
showed	show	VBD	B-VP	O
EF	EF	NN	B-NP	O
58	58	CD	B-NP	O
%	%	NN	I-NP	O
with	with	IN	B-PP	O
small	small	JJ	B-NP	O
area	area	NN	I-NP	O
of	of	IN	B-PP	O
scarring	scar	VBG	B-VP	O
unchanged	unchanged	JJ	B-ADJP	O
from	from	IN	B-PP	O
previous	previous	JJ	B-NP	O
study	study	NN	I-NP	O
in	in	IN	B-PP	O
2004	2004	CD	B-NP	O
.	.	.	O	O

Continued	Continue	VBN	B-NP	O
home	home	NN	I-NP	O
regimen	regimen	NN	I-NP	O
of	of	IN	B-PP	O
ASA	ASA	NNP	B-NP	O
,	,	,	O	O
Labetalol	Labetalol	NNP	B-NP	O
,	,	,	O	O
Candesartan	Candesartan	NNP	B-NP	O
,	,	,	O	O
Lisinopril	Lisinopril	NNP	B-NP	O
,	,	,	O	O
Norvasc	Norvasc	NNP	B-NP	O
,	,	,	O	O
and	and	CC	O	O
Plavix	Plavix	NNP	B-NP	O
.	.	.	O	O

Substituted	Substitute	VBN	B-NP	O
Simvastatin	Simvastatin	NN	I-NP	O
for	for	IN	B-PP	O
Lipitor	Lipitor	NN	B-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

CV	CV	NN	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
P	P	NN	I-NP	O
-RRB-	-RRB-	NN	I-NP	O
:	:	:	O	O
On	On	IN	B-PP	O
admission	admission	NN	B-NP	O
,	,	,	O	O
pt	pt	NN	B-NP	O
appeared	appear	VBD	B-VP	O
euvolemic	euvolemic	JJ	B-ADJP	O
on	on	IN	B-PP	O
exam	exam	NN	B-NP	O
,	,	,	O	O
with	with	IN	B-PP	O
significant	significant	JJ	B-NP	O
hypertension	hypertension	NN	I-NP	O
,	,	,	O	O
thought	think	VBN	B-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
secondary	secondary	JJ	B-ADJP	O
to	to	TO	B-VP	O
pain	pain	VB	I-VP	O
.	.	.	O	O

Continued	Continue	VBN	B-NP	O
home	home	NN	I-NP	O
hypertensive	hypertensive	JJ	I-NP	O
regimen	regimen	NN	I-NP	O
,	,	,	O	O
as	as	RB	B-CONJP	O
well	well	RB	I-CONJP	O
as	as	IN	I-CONJP	O
Lasix	Lasix	NNP	B-NP	O
40mg	40mg	CD	I-NP	O
BID	BID	NNP	I-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
's	's	POS	B-NP	O
hypertension	hypertension	NN	I-NP	O
did	do	VBD	B-VP	O
improve	improve	VB	I-VP	O
with	with	IN	B-PP	O
pain	pain	NN	B-NP	O
control	control	NN	I-NP	O
.	.	.	O	O

However	However	RB	B-ADVP	O
,	,	,	O	O
pt	pt	NN	B-NP	O
's	's	POS	B-NP	O
creatinine	creatinine	NN	I-NP	O
increased	increase	VBD	B-VP	O
from	from	IN	B-PP	O
1.2	1.2	CD	B-NP	O
to	to	TO	B-PP	O
1.8	1.8	CD	B-NP	O
and	and	CC	O	O
pt	pt	NN	B-NP	O
appeared	appear	VBD	B-VP	O
dry	dry	JJ	B-ADJP	O
on	on	IN	B-PP	O
3rd	3rd	JJ	B-NP	O
day	day	NN	I-NP	O
of	of	IN	B-PP	O
admission	admission	NN	B-NP	O
.	.	.	O	O

Lasix	Lasix	NN	B-NP	O
was	be	VBD	B-VP	O
held	hold	VBN	I-VP	O
and	and	CC	O	O
pt	pt	NN	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
gentle	gentle	JJ	B-NP	O
IVF	IVF	NN	I-NP	O
,	,	,	O	O
which	which	WDT	B-NP	O
resolved	resolve	VBD	B-VP	O
ARF	ARF	NN	B-NP	B-protein
to	to	TO	B-PP	O
Cr	Cr	NN	B-NP	B-protein
1.3	1.3	CD	I-NP	I-protein
.	.	.	O	O

Pt	Pt	NN	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
instructed	instruct	VBN	I-VP	O
to	to	TO	I-VP	O
hold	hold	VB	I-VP	O
her	her	PRP	B-NP	O
Lasix	Lasix	NNP	B-NP	O
until	until	IN	B-PP	O
Monday	Monday	NNP	B-NP	O
5/18/07	5/18/07	CD	I-NP	O
,	,	,	O	O
upon	upon	IN	B-PP	O
which	which	WDT	B-NP	O
she	she	PRP	B-NP	O
will	will	MD	B-VP	O
resume	resume	VB	I-VP	O
at	at	IN	B-PP	O
40mg	40mg	CD	B-NP	O
daily	daily	RB	I-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
will	will	MD	B-VP	O
follow-up	follow-up	VB	I-VP	O
with	with	IN	B-PP	O
her	her	PRP$	B-NP	O
PCP	PCP	NN	I-NP	B-protein
next	next	IN	B-NP	O
week	week	NN	I-NP	O
to	to	TO	B-VP	O
assess	assess	VB	I-VP	O
need	need	NN	B-NP	O
to	to	TO	B-VP	O
adjust	adjust	VB	I-VP	O
Lasix	Lasix	NN	B-NP	O
dosing	dosing	NN	I-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

CV	CV	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
R	R	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
:	:	:	O	O
Monitored	Monitor	VBN	B-VP	O
on	on	IN	B-PP	O
telemetry	telemetry	NN	B-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
events	event	NNS	I-NP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

GI	GI	LS	B-LST	O
:	:	:	O	O
No	No	DT	B-NP	O
active	active	JJ	I-NP	O
issues	issue	NNS	I-NP	O
.	.	.	O	O

Continued	Continued	NNP	B-NP	O
PPI	PPI	NNP	I-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

PAIN	PAIN	NN	B-NP	B-protein
:	:	:	O	O
Continued	Continue	VBN	B-NP	O
home	home	NN	I-NP	O
pain	pain	NN	I-NP	O
med	me	VBD	B-VP	O
regimen	regimen	NN	B-NP	O
of	of	IN	B-PP	O
Oxycontin	Oxycontin	NN	B-NP	O
60mg	60mg	NN	I-NP	O
q8h	q8h	NN	I-NP	O
plus	plus	CC	O	O
oxycodone	oxycodone	NN	B-NP	O
5-10mg	5-10mg	JJ	I-NP	O
q4-6h	q4-6h	NN	I-NP	O
prn	prn	NN	I-NP	O
for	for	IN	B-PP	O
breakthrough	breakthrough	NN	B-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
continued	continue	VBD	B-VP	O
to	to	TO	I-VP	O
have	have	VB	I-VP	O
significant	significant	JJ	B-NP	O
pain	pain	NN	I-NP	O
which	which	WDT	B-NP	O
presented	present	VBD	B-VP	O
in	in	IN	B-PP	O
different	different	JJ	B-NP	O
locations	location	NNS	I-NP	O
.	.	.	O	O

Most	Most	JJS	B-NP	O
significant	significant	JJ	I-NP	O
was	be	VBD	B-VP	O
right	right	JJ	B-NP	O
breast/right	breast/right	NN	I-NP	O
underarm	underarm	NN	I-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

Suspected	Suspect	VBN	B-NP	O
etiology	etiology	NN	I-NP	O
of	of	IN	B-PP	O
this	this	DT	B-NP	O
pain	pain	NN	I-NP	O
is	be	VBZ	B-VP	O
exacerbation	exacerbation	NN	B-NP	O
of	of	IN	B-PP	O
chronic	chronic	JJ	B-NP	O
pain	pain	NN	I-NP	O
syndrome	syndrome	NN	I-NP	O
vs	vs	IN	B-PP	O
musculoskeletal	musculoskeletal	NN	B-NP	O
.	.	.	O	O

Heating	Heat	VBG	B-NP	O
pads	pad	NNS	I-NP	O
offered	offer	VBD	B-VP	O
some	some	DT	B-NP	O
relief	relief	NN	I-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
's	's	POS	B-NP	O
pain	pain	NN	I-NP	O
was	be	VBD	B-VP	O
improved	improve	VBN	I-VP	O
by	by	IN	B-PP	O
discharge	discharge	NN	B-NP	O
with	with	IN	B-PP	O
no	no	DT	B-NP	O
specific	specific	JJ	I-NP	O
intervention	intervention	NN	I-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
will	will	MD	B-VP	O
follow-up	follow-up	VB	I-VP	O
with	with	IN	B-PP	O
PCP	PCP	NN	B-NP	O
to	to	TO	B-VP	O
assess	assess	VB	I-VP	O
resolution	resolution	NN	B-NP	O
of	of	IN	B-PP	O
pain	pain	NN	B-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

PSYCH	PSYCH	NN	B-NP	B-protein
:	:	:	O	O
Pt	Pt	NN	B-NP	O
has	have	VBZ	B-VP	O
significant	significant	JJ	B-NP	O
anxiety	anxiety	NN	I-NP	O
regarding	regard	VBG	B-VP	O
lack	lack	NN	B-NP	O
of	of	IN	B-PP	O
specific	specific	JJ	B-NP	O
diagnosis	diagnosis	NN	I-NP	O
for	for	IN	B-PP	O
her	her	PRP$	B-NP	O
increased	increase	VBN	I-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

Also	Also	RB	B-ADVP	O
expresses	express	VBZ	B-VP	O
considerable	considerable	JJ	B-NP	O
amount	amount	NN	I-NP	O
of	of	IN	B-PP	O
anxiety/depression	anxiety/depression	NN	B-NP	O
over	over	IN	B-PP	O
life	life	NN	B-NP	O
stressors	stressor	NNS	I-NP	O
-LRB-	-LRB-	VBP	B-VP	O
son	son	NN	B-NP	O
in	in	IN	B-PP	O
Sterl	Sterl	NNP	B-NP	O
Tuc	Tuc	NNP	I-NP	O
Wau	Wau	NNP	I-NP	O
,	,	,	O	O
recent	recent	JJ	B-NP	O
death	death	NN	I-NP	O
of	of	IN	B-PP	O
sister	sister	NN	B-NP	B-protein
-RRB-	-RRB-	NN	I-NP	I-protein
.	.	.	O	O

Suspect	Suspect	VB	B-VP	O
that	that	DT	B-NP	O
anxiety/depression	anxiety/depression	NN	I-NP	O
may	may	MD	B-VP	O
be	be	VB	I-VP	O
significantly	significantly	RB	B-ADJP	O
contributing	contribute	VBG	I-ADJP	O
to	to	TO	B-PP	O
increased	increase	VBN	B-NP	O
pain	pain	NN	I-NP	O
.	.	.	O	O

Psychiatry	Psychiatry	NN	B-NP	O
was	be	VBD	B-VP	O
consulted	consult	VBN	I-VP	O
who	who	WP	B-NP	O
felt	feel	VBD	B-VP	O
that	that	DT	B-NP	O
pt	pt	NN	I-NP	O
was	be	VBD	B-VP	O
expressing	express	VBG	I-VP	O
normal	normal	JJ	B-NP	O
bereavement	bereavement	NN	I-NP	O
and	and	CC	O	O
that	that	IN	B-SBAR	O
anti-depressant	anti-depressant	JJ	B-NP	O
medication	medication	NN	I-NP	O
was	be	VBD	B-VP	O
not	not	RB	I-VP	O
indicated	indicate	VBN	I-VP	O
at	at	IN	B-PP	O
this	this	DT	B-NP	O
time	time	NN	I-NP	O
.	.	.	O	O

They	They	PRP	B-NP	O
recommended	recommend	VBD	B-VP	O
follow-up	follow-up	NN	B-NP	O
in	in	IN	B-PP	O
the	the	DT	B-NP	O
Psychiatry	Psychiatry	NN	I-NP	O
outpatient	outpatient	NN	I-NP	O
clinic	clinic	NN	I-NP	O
,	,	,	O	O
for	for	IN	B-PP	O
which	which	WDT	B-NP	O
the	the	DT	B-NP	O
patient	patient	NN	I-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
provided	provide	VBN	I-VP	O
a	a	DT	B-NP	O
phone	phone	NN	I-NP	O
number	number	NN	I-NP	O
to	to	TO	B-VP	O
call	call	VB	I-VP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
felt	feel	VBD	B-VP	O
significant	significant	JJ	B-NP	O
improvement	improvement	NN	I-NP	O
of	of	IN	B-PP	O
anxiety	anxiety	NN	B-NP	O
after	after	IN	B-PP	O
talking	talk	VBG	B-VP	O
to	to	TO	B-PP	O
Psychiatry	Psychiatry	NN	B-NP	O
consult	consult	NN	I-NP	O
.	.	.	O	O

Psych	Psych	NNP	B-NP	O
recommended	recommend	VBD	B-VP	O
Ativan	Ativan	NNP	B-NP	O
prn	prn	NN	I-NP	O
for	for	IN	B-PP	O
anxiety	anxiety	NN	B-NP	O
,	,	,	O	O
and	and	CC	O	O
pt	pt	NN	B-NP	O
was	be	VBD	B-VP	O
given	give	VBN	I-VP	O
prescription	prescription	NN	B-NP	O
for	for	IN	B-PP	O
Ativan	Ativan	NNP	B-NP	O
0.5	0.5	CD	I-NP	O
mg	mg	NN	I-NP	O
PO	PO	NN	I-NP	O
prn	prn	NN	I-NP	O
for	for	IN	B-PP	O
anxiety	anxiety	NN	B-NP	O
.	.	.	O	O

7	7	CD	B-NP	O
.	.	.	O	O

RENAL	RENAL	NN	B-NP	O
:	:	:	O	O
Pt	Pt	NN	B-NP	O
had	have	VBD	B-VP	O
ARF	ARF	NN	B-NP	B-protein
on	on	IN	B-PP	O
day	day	NN	B-NP	O
3	3	CD	I-NP	O
with	with	IN	B-PP	O
increased	increase	VBN	B-NP	O
Cr	Cr	NN	I-NP	B-protein
1.8	1.8	CD	I-NP	I-protein
up	up	RB	B-ADVP	O
from	from	IN	B-PP	O
1.3	1.3	CD	B-NP	O
.	.	.	O	O

Likely	Likely	JJ	B-NP	O
dehydration	dehydration	NN	I-NP	O
as	as	IN	B-SBAR	O
pt	pt	NN	B-NP	O
appeared	appear	VBD	B-VP	O
clinically	clinically	RB	B-ADJP	O
dry	dry	JJ	I-ADJP	O
.	.	.	O	O

Gave	Gave	NN	B-NP	B-protein
IVF	IVF	NN	I-NP	I-protein
and	and	CC	O	O
held	hold	VBD	B-VP	O
Lasix	Lasix	NNP	B-NP	O
.	.	.	O	O

Renal	Renal	JJ	B-NP	O
U/S	U/S	NN	I-NP	O
was	be	VBD	B-VP	O
normal	normal	JJ	B-ADJP	O
ruling	rule	VBG	B-VP	O
out	out	RP	B-PRT	O
obstuctive	obstuctive	JJ	B-NP	O
etiology	etiology	NN	I-NP	O
.	.	.	O	O

With	With	IN	B-PP	O
hydration	hydration	NN	B-NP	O
,	,	,	O	O
pt	pt	NN	B-NP	O
creatinine	creatinine	NN	I-NP	O
normalized	normalize	VBD	B-VP	O
to	to	TO	B-PP	O
1.3	1.3	CD	B-NP	O
on	on	IN	B-PP	O
day	day	NN	B-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
will	will	MD	B-VP	O
hold	hold	VB	I-VP	O
Lasix	Lasix	NNP	B-NP	O
until	until	IN	B-PP	O
Monday	Monday	NNP	B-NP	O
5/18/07	5/18/07	CD	I-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
resume	resume	VB	B-VP	O
at	at	IN	B-PP	O
40mg	40mg	CD	B-NP	O
daily	daily	RB	I-NP	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
will	will	MD	B-VP	O
follow-up	follow-up	VB	I-VP	O
with	with	IN	B-PP	O
PCP	PCP	NN	B-NP	O
regarding	regard	VBG	B-PP	O
adjusting	adjust	VBG	B-VP	O
Lasix	Lasix	NNP	B-NP	O
dosing	dosing	NN	I-NP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
.	.	.	O	O

FULL	FULL	NN	B-NP	O
CODE	CODE	NN	I-NP	O
ADDITIONAL	ADDITIONAL	NN	I-NP	O
COMMENTS	COMMENTS	NNS	I-NP	O
:	:	:	O	O
FOR	FOR	NN	B-NP	O
VNA	VNA	NN	I-NP	O
:	:	:	O	O
Monitor	Monitor	NN	B-NP	O
pt	pt	NN	I-NP	O
's	's	POS	B-NP	O
vital	vital	JJ	I-NP	O
signs	sign	NNS	I-NP	O
,	,	,	O	O
volume	volume	NN	B-NP	O
status	status	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
general	general	JJ	B-NP	O
pain	pain	NN	I-NP	O
assessment	assessment	NN	I-NP	O
.	.	.	O	O

--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
FOR	FOR	IN	B-PP	O
PATIENT	PATIENT	NN	B-NP	O
:	:	:	O	O
1	1	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-VP	O
call	call	VB	I-VP	O
your	your	PRP$	B-NP	O
doctor	doctor	NN	I-NP	O
if	if	IN	B-SBAR	O
you	you	PRP	B-NP	O
experience	experience	VBP	B-VP	O
worsening	worsen	VBG	I-VP	O
chest	chest	NN	B-NP	O
pain	pain	NN	I-NP	O
,	,	,	O	O
shortness	shortness	NN	B-NP	O
of	of	IN	B-PP	O
breath	breath	NN	B-NP	O
,	,	,	O	O
fainting	fainting	NN	B-NP	O
,	,	,	O	O
lightheadedness	lightheadedness	NN	B-NP	O
,	,	,	O	O
or	or	CC	O	O
other	other	JJ	B-NP	O
concerning	concern	VBG	I-NP	O
symptoms	symptom	NNS	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Please	Please	NN	B-NP	B-protein
do	do	VBP	B-VP	O
not	not	RB	I-VP	O
take	take	VB	I-VP	O
your	your	PRP$	B-NP	O
Lasix	Lasix	NNP	I-NP	O
until	until	IN	B-PP	O
Monday	Monday	NNP	B-NP	O
5/18/07	5/18/07	CD	I-NP	O
.	.	.	O	O

On	On	IN	B-PP	O
Monday	Monday	NNP	B-NP	O
,	,	,	O	O
please	please	NN	B-NP	O
resume	resume	VBP	B-VP	O
Lasix	Lasix	NNP	B-NP	O
at	at	IN	B-PP	O
40mg	40mg	CD	B-NP	O
once	once	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

We	We	PRP	B-NP	O
have	have	VBP	B-VP	O
started	start	VBN	I-VP	O
you	you	PRP	B-NP	O
on	on	IN	B-PP	O
Senna	Senna	NNP	B-NP	O
2	2	CD	I-NP	O
tabs	tab	NNS	I-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
for	for	IN	B-PP	O
constipation	constipation	NN	B-NP	O
in	in	IN	B-PP	O
addition	addition	NN	B-NP	O
to	to	TO	B-PP	O
the	the	DT	B-NP	O
Colace	Colace	NNP	I-NP	O
100mg	100mg	CD	I-NP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
that	that	IN	B-SBAR	O
you	you	PRP	B-NP	O
have	have	VBP	B-VP	O
been	be	VBN	I-VP	O
taking	take	VBG	I-VP	O
.	.	.	O	O

If	If	IN	B-SBAR	O
you	you	PRP	B-NP	O
become	become	VBP	B-VP	O
constipated	constipate	VBN	B-ADJP	O
,	,	,	O	O
you	you	PRP	B-NP	O
can	can	MD	B-VP	O
take	take	VB	I-VP	O
Dulcolax	Dulcolax	NNP	B-NP	O
5mg	5mg	CD	I-NP	O
once	once	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
.	.	.	O	O

4	4	LS	B-LST	O
.	.	.	O	O

We	We	PRP	B-NP	O
have	have	VBP	B-VP	O
given	give	VBN	I-VP	O
you	you	PRP	B-NP	O
a	a	DT	B-NP	O
prescription	prescription	NN	I-NP	O
for	for	IN	B-PP	O
Ativan	Ativan	NNP	B-NP	O
0.5	0.5	CD	I-NP	O
mg	mg	NN	I-NP	O
to	to	TO	B-VP	O
use	use	VB	I-VP	O
as	as	IN	B-SBAR	O
needed	need	VBN	B-VP	O
twice	twice	RB	B-ADVP	O
daily	daily	RB	I-ADVP	O
for	for	IN	B-PP	O
anxiety	anxiety	NN	B-NP	O
.	.	.	O	O

5	5	LS	B-LST	O
.	.	.	O	O

Please	Please	VB	B-VP	O
call	call	VB	I-VP	O
you	you	PRP	B-NP	O
PCP	PCP	NN	B-NP	O
to	to	TO	B-VP	O
make	make	VB	I-VP	O
an	an	DT	B-NP	O
appt	appt	NN	I-NP	O
next	next	JJ	B-NP	O
week	week	NN	I-NP	O
to	to	TO	B-VP	O
assess	assess	VB	I-VP	O
your	your	PRP$	B-NP	O
pain	pain	NN	I-NP	O
and	and	CC	I-NP	O
need	need	NN	I-NP	O
for	for	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
dosing	dosing	NN	I-NP	O
.	.	.	O	O

6	6	CD	B-NP	O
.	.	.	O	O

Please	Please	VB	B-VP	O
call	call	VB	I-VP	O
the	the	DT	B-NP	O
Psychiatry	Psychiatry	NNP	I-NP	O
outpatient	outpatient	NN	I-NP	O
clinic	clinic	NN	I-NP	O
to	to	TO	B-VP	O
make	make	VB	I-VP	O
an	an	DT	B-NP	O
appointment	appointment	NN	I-NP	O
.	.	.	O	O

DISCHARGE	DISCHARGE	NN	B-NP	O
CONDITION	CONDITION	NN	I-NP	O
:	:	:	O	O
Stable	Stable	JJ	B-NP	O
TO	TO	NN	I-NP	O
DO/PLAN	DO/PLAN	NN	I-NP	O
:	:	:	O	O
FOR	FOR	NN	B-NP	O
VNA	VNA	NN	I-NP	O
:	:	:	O	O
Monitor	Monitor	NN	B-NP	O
pt	pt	NN	I-NP	O
's	's	POS	B-NP	O
vital	vital	JJ	I-NP	O
signs	sign	NNS	I-NP	O
,	,	,	O	O
volume	volume	NN	B-NP	O
status	status	NN	I-NP	O
,	,	,	O	O
and	and	CC	O	O
general	general	JJ	B-NP	O
pain	pain	NN	I-NP	O
assessment	assessment	NN	I-NP	O
.	.	.	O	O

--	--	:	O	O
--	--	:	O	O
--	--	:	O	O
FOR	FOR	IN	B-PP	O
PCP	PCP	NN	B-NP	B-protein
:	:	:	O	I-protein
1	1	LS	B-LST	I-protein
.	.	.	O	O

Pt	Pt	NNP	B-NP	O
's	's	POS	B-NP	O
Lasix	Lasix	NNP	I-NP	O
held	hold	VBD	B-VP	O
until	until	IN	B-PP	O
Monday	Monday	NNP	B-NP	O
5/18/07	5/18/07	CD	I-NP	O
,	,	,	O	O
then	then	RB	B-ADVP	O
restarted	restart	VBD	B-VP	O
at	at	IN	B-PP	O
Lasix	Lasix	NNP	B-NP	O
40mg	40mg	CC	O	O
daily	daily	JJ	B-NP	O
-LRB-	-LRB-	NN	I-NP	O
down	down	RB	B-ADVP	O
from	from	IN	B-PP	O
prior	prior	JJ	B-NP	B-protein
40mg	40mg	NN	I-NP	I-protein
BID	BID	NN	I-NP	I-protein
dosing	dosing	NN	I-NP	I-protein
-RRB-	-RRB-	NN	I-NP	I-protein
due	due	IN	B-PP	O
to	to	TO	I-PP	O
ARF	ARF	NN	B-NP	B-protein
with	with	IN	B-PP	O
Cr	Cr	NN	B-NP	B-protein
1.8	1.8	CD	I-NP	I-protein
.	.	.	O	O

Cr	Cr	NN	B-NP	O
1.3	1.3	CD	I-NP	O
and	and	CC	O	O
K	K	NN	B-NP	B-protein
3.8	3.8	CD	I-NP	I-protein
on	on	IN	B-PP	O
day	day	NN	B-NP	O
of	of	IN	B-PP	O
discharge	discharge	NN	B-NP	O
.	.	.	O	O

Creatinine	Creatinine	NN	B-NP	O
and	and	CC	I-NP	O
Potassium	Potassium	NN	I-NP	O
will	will	MD	B-VP	O
need	need	VB	I-VP	O
to	to	TO	I-VP	O
be	be	VB	I-VP	O
rechecked	rechecke	VBN	I-VP	O
next	next	JJ	B-NP	O
week	week	NN	I-NP	O
and	and	CC	O	O
Lasix	Lasix	NN	B-NP	O
dosing	dosing	NN	I-NP	O
adjusted	adjust	VBN	B-VP	O
according	accord	VBG	B-VP	O
to	to	TO	I-VP	O
pt	pt	VB	I-VP	O
's	's	POS	B-NP	O
volume	volume	NN	I-NP	O
status	status	NN	I-NP	O
.	.	.	O	O

2	2	LS	B-LST	O
.	.	.	O	O

Reassess	Reassess	NN	B-NP	O
pain	pain	NN	I-NP	O
med	me	VBD	B-VP	O
regimen	regimen	NN	B-NP	O
.	.	.	O	O

3	3	LS	B-LST	O
.	.	.	O	O

Pt	Pt	NN	B-NP	O
need	need	VBP	B-VP	O
outpatient	outpatient	JJ	B-NP	O
Psychiatry	Psychiatry	NNP	I-NP	O
follow-up	follow-up	NN	I-NP	O
for	for	IN	B-PP	O
depression/anxiety	depression/anxiety	NN	B-NP	O
.	.	.	O	O

She	She	PRP	B-NP	O
has	have	VBZ	B-VP	O
been	be	VBN	I-VP	O
provided	provide	VBN	I-VP	O
with	with	IN	B-PP	O
phone	phone	NN	B-NP	O
number	number	NN	I-NP	O
for	for	IN	B-PP	O
outpatient	outpatient	NN	B-NP	O
Psych	Psych	NN	I-NP	O
clinic	clinic	NN	I-NP	O
to	to	TO	B-VP	O
schedule	schedule	VB	I-VP	O
an	an	DT	B-NP	O
appt	appt	NN	I-NP	O
.	.	.	O	O

No	No	DT	B-NP	O
dictated	dictated	JJ	I-NP	O
summary	summary	NN	I-NP	O
ENTERED	ENTERED	NNP	I-NP	O
BY	BY	NNP	I-NP	O
:	:	:	O	O
WOLDRIDGE	WOLDRIDGE	NNP	B-NP	O
,	,	,	O	O
MARQUIS	MARQUIS	NNP	B-NP	O
B.	B.	NNP	I-NP	O
,	,	,	O	O
M.D.	M.D.	NNP	B-NP	O
,	,	,	O	O
PH.D.	PH.D.	NNP	B-NP	O
-LRB-	-LRB-	NNP	I-NP	O
YM68	YM68	NNP	I-NP	O
-RRB-	-RRB-	NNP	I-NP	O
10/25/07	10/25/07	CD	I-NP	O
@	@	NN	I-NP	O
06	06	CD	I-NP	O
:	:	:	O	O
03	03	CD	B-NP	O
PM	PM	NN	I-NP	O
******	******	SYM	B-NP	O
END	END	NN	I-NP	O
OF	OF	IN	B-PP	O
DISCHARGE	DISCHARGE	NN	B-NP	O
ORDERS	ORDERS	NNS	I-NP	O
******	******	SYM	B-NP	O

